The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
An article from
Dive Brief
The RNA-focused drugmaker says Inceptive’s tools will help prioritize the best development options as well as speed up the research process.
Published June 4, 2026
By
Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish…
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if…
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity…
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main…
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
